ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
244.76
-1.46 (-0.59%)
At close: May 28, 2025, 4:00 PM
245.16
+0.40 (0.17%)
After-hours: May 28, 2025, 4:30 PM EDT
ResMed Revenue
ResMed had revenue of $1.29B in the quarter ending March 31, 2025, with 7.92% growth. This brings the company's revenue in the last twelve months to $5.02B, up 9.54% year-over-year. In the fiscal year ending June 30, 2024, ResMed had annual revenue of $4.69B with 10.95% growth.
Revenue (ttm)
$5.02B
Revenue Growth
+9.54%
P/S Ratio
7.20
Revenue / Employee
$503,159
Employees
9,980
Market Cap
35.88B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 4.69B | 462.30M | 10.95% |
Jun 30, 2023 | 4.22B | 644.87M | 18.02% |
Jun 30, 2022 | 3.58B | 381.30M | 11.93% |
Jun 30, 2021 | 3.20B | 239.81M | 8.11% |
Jun 30, 2020 | 2.96B | 350.44M | 13.44% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RMD News
- 13 days ago - Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025 - GlobeNewsWire
- 26 days ago - Top 15 High-Growth Dividend Stocks To Consider For May 2025 - Seeking Alpha
- 27 days ago - Resmed Acquires VirtuOx - GlobeNewsWire
- 4 weeks ago - ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast - Benzinga
- 4 weeks ago - ResMed: Cornering The Market In Sleep Solutions - Seeking Alpha
- 4 weeks ago - ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - ResMed slightly beats quarterly profit estimates on sleep devices demand - Reuters
- 5 weeks ago - Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025 - GlobeNewsWire